Cochrane · systematic review · CD006053
Pylorus‐preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma
Hüttner, FJ, Fitzmaurice, C, Schwarzer, G, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 6 · 85.7%Moderate 1 · 14.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyPostoperative mortality and DGE after surgical treatment for periampullary or pancreatic carcinoma
Population: people with surgical treatment for periampullary or pancreatic carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Postoperative mortality | OR 0.64 [0.26, 1.54] | 7 studies · 464 participants | Moderate Downgraded: imprecision |
Pancreatic fistula | OR 0.95 [0.49, 1.84] | 7 studies · 468 participants | Low Downgraded: imprecision, inconsistency |
DGE | OR 3.03 [1.05, 8.7] | 7 studies · 459 participants | Low Downgraded: imprecision, inconsistency |
Survival after surgical treatment for periampullary or pancreatic carcinoma
Population: people with surgical treatment for periampullary or pancreatic carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival | HR 0.84 [0.61, 1.16] | 3 studies · 284 participants | Low Downgraded: risk of bias, imprecision |
Operating time, intraoperative blood loss, and red blood cell transfusion in surgical treatment for periampullary or pancreatic carcinoma
Population: people with surgical treatment for periampullary or pancreatic carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intraoperative blood loss (millilitres) | no estimate extracted | 5 studies · 404 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Red blood cell transfusion (units) | no estimate extracted | 5 studies · 273 participants | Low Downgraded: risk of bias, imprecision |
Operating time (minutes) | no estimate extracted | 7 studies · 472 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Survival after surgical treatment for periampullary or pancreatic carcinoma
Population: patients with surgical treatment of periampullary or pancreatic carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival | HR 0.84 [0.61, 1.16] | 0 studies · 3 participants | Low Downgraded: risk of bias, imprecision |
Mortality after surgical treatment for periampullary or pancreatic carcinoma
Population: patients with surgical treatment for periampullary and pancreatic carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Postoperative mortality | OR 0.49 [0.17, 1.4] | 5 studies · 417 participants | Low Downgraded: imprecision, publication bias |
Intraoperative blood loss in surgical treatment of patients with periampullary or pancreatic carcinoma
Population: patients with surgical treatment for periampullary or pancreatic carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intraoperative blood loss (litres) | no estimate extracted | 1 study · 33 participants | Low Downgraded: imprecision, publication bias |
Operating time in surgical treatment for periampullary or pancreatic carcinoma
Population: patients with surgical treatment for periampullary and pancreatic carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Operating time (minutes) | no estimate extracted | 3 studies · 125 participants | Low Downgraded: risk of bias, imprecision, publication bias |
Survival after surgical treatment of periampullary or pancreatic carcinoma
Population: patients with surgical treatment of periampullary and pancreatic carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival | HR 0.84 [0.61, 1.16] | 0 studies · 3 participants | Low Downgraded: risk of bias, imprecision |
Mortality after surgical treatment of periampullary or pancreatic carcinoma
Population: patients with surgical treatment of periampullary and pancreatic carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Postoperative mortality | OR 0.49 [0.17, 1.4] | 5 studies · 417 participants | Low Downgraded: imprecision, publication bias |
Intra‐operative blood loss in surgical treatment of patients with periampullary or pancreatic carcinoma
Population: patients with surgical treatment of patients with periampullary or pancreatic carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intra‐operative blood loss (litres) | no estimate extracted | 1 study · 33 participants | Low Downgraded: imprecision, publication bias |
Operating time in surgical treatment of periampullary or pancreatic carcinoma
Population: patients with surgical treatment of periampullary and pancreatic carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Operating time (minutes) | no estimate extracted | 3 studies · 125 participants | Low Downgraded: risk of bias, imprecision, publication bias |